Gonadorelin (GnRH)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Gonadorelin (GnRH) is listed as hormonal / gnrh agonist.
- •Hypogonadism diagnostics
- •HPTA maintenance
- •Fertility support during androgen therapy
Regulatory status: FDA-Approved Rx (diagnostic); off-label HPTA use common.
Structure & Properties
Compound: Gonadorelin (GnRH); also known as LHRH, Factrel.
Pharmacologic class: Hormonal / GnRH Agonist.
Known delivery routes: Subcutaneous, Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Synthetic gonadotropin-releasing hormone; pulsatile dosing stimulates pituitary LH/FSH release, preserving testicular function.
- •Maintains endogenous LH/FSH signaling
- •Preserves testicular volume and fertility markers
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Well characterized endocrine agent.
Laboratory Research
Well characterized endocrine agent
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Continuous (non-pulsatile) dosing downregulates the axis
- •Headache, flushing
- •Injection-site reaction
Contraindications
- •Hormone-sensitive malignancy
- •Pregnancy
- •Undiagnosed abnormal vaginal bleeding
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100 mcg per dose (diagnostic); 100–200 mcg 2–3×/week off-label
Frequency: Pulsatile — every 2–3 days or per protocol
Cycling: Pulsatile only. Continuous daily dosing paradoxically suppresses gonadotropins.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Intravenous (IV)
Clinician-administered only. Reserved for hospital protocols, senolytics research, or emergency use.
IV catheter / infusion pump. Sterile IV push or slow infusion per protocol. Not for home use.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Gonadorelin (GnRH)?
In plain words
Gonadorelin is a lab-made version of a hormone that signals the body's reproductive system. The pituitary gland responds to signals in pulses by releasing hormones that help maintain testicular function, while continuous exposure can weaken this response. It is approved for testing low sex-hormone function and is also studied for maintaining the hormone signals that control the testes. Evidence from controlled trials is limited, and side effects include headache, flushing, and reactions where it is injected.
Technical definition
Gonadorelin (GnRH), also known as LHRH or Factrel, is a synthetic gonadotropin-releasing hormone and GnRH receptor agonist acting at the pituitary to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. Pulsatile exposure supports testicular function, whereas continuous exposure downregulates the hypothalamic-pituitary-testicular axis (HPTA). It is FDA-approved as a prescription diagnostic agent for hypogonadism; HPTA maintenance is a common off-label use, with limited randomized clinical trial evidence.
Function
Dosing
Recommended Time of Day
As prescribed — typically pulsed or 2–3× weekly morning dosing.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Pulsatile only. Continuous daily dosing paradoxically suppresses gonadotropins.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Gonadorelin (GnRH) and sync them to Vial Lab.
Benefits
- ·Maintains endogenous LH/FSH signaling
- ·Preserves testicular volume and fertility markers
Risks
- ·Continuous (non-pulsatile) dosing downregulates the axis
- ·Headache, flushing
- ·Injection-site reaction
Contraindications
- ·Hormone-sensitive malignancy
- ·Pregnancy
- ·Undiagnosed abnormal vaginal bleeding
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx (diagnostic); off-label HPTA use common
Veterinary Use (Pets)
No established veterinary protocol for Gonadorelin (GnRH). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.